FDA Often Looks Outside The Application, Review Documents Show
Executive Summary
A look back at drug reviews in the past year illustrates the many ways FDA takes external factors into consideration when reviewing an application – from guiding trials to look for certain class safety signals to finding support for a particular endpoint.
You may also be interested in...
AstraZeneca’s Farxiga Label Includes, But Downplays, Bladder Cancer Risk
AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.
The Next Phase In Oncology: FDA’s Pazdur Has New Vision For Drug Development
FDA’s top cancer drug reviewer has taken to the podium to paint a picture of the next phase in cancer drug development, which includes new business models, a return to single-arm trials and a new emphasis on safety.
Accelerated And Accompanied: Oncology Drugs Should Use Randomized Trials, FDA Panel Says
Single-arm studies for accelerated approval should be used only when the patient population is small or drug activity is high, the Oncology Drugs Advisory Committee says.